Literature DB >> 7027431

Bromhexine treatment of Sjögren's syndrome: effect on lacrimal and salivary secretion, and on proteins in tear fluid and saliva.

R Manthorpe, K Frost-Larsen, L Høj, H Isager, J U Prause.   

Abstract

In a randomized clinical study, 32 patients with Sögren's syndrome (SS were given placebo/bromhexine (Bisolvon) 48 mg daily for 3 weeks. Various ophthalmological and oral variables as well as different proteins in the tear fluid and saliva were registered. Bromhexine stimulated the tear secretion significantly, presumable without changing the protein composition of the tear fluid. In contrast to other proteins in saliva the IgM concentration decreased in patients with high pre-treatment values. Bromhexine may be of valuable help in the treatment of some patients with SS.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7027431     DOI: 10.3109/03009748109095294

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  4 in total

1.  [Revision of the recommendations of the Commission on Pharmacotherapy of the German Society for Rheumatology. Recommendations for supportive therapy for Sjögren's syndrome].

Authors:  A Gause
Journal:  Z Rheumatol       Date:  2007-02       Impact factor: 1.372

Review 2.  Rational drug therapy recommendations for the treatment of patients with Sjögren's syndrome.

Authors:  P Oxholm; J U Prause; M Schiødt
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

3.  Nonneoplastic disorders of the parotid gland.

Authors:  D Lundeberg
Journal:  West J Med       Date:  1983-04

4.  Primary Sjögren's syndrome treated with Efamol/Efavit. A double-blind cross-over investigation.

Authors:  R Manthorpe; S Hagen Petersen; J U Prause
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.